Hematology

Latest News

Ibrutinib Plus Venetoclax Provides Survival Benefit in CLL
Ibrutinib Plus Venetoclax Provides Survival Benefit in CLL

March 23rd 2024

Progression-free and overall survival benefits were obtained with MRD-guided ibrutinib plus venetoclax when compared with fludarabine plus cyclophosphamide and rituximab in chronic lymphocytic leukemia.

Venetoclax Results in Durable Efficacy for Relapsed/Refractory CLL
Venetoclax Results in Durable Efficacy for Relapsed/Refractory CLL

March 20th 2024

FDA ODAC Committee’s 12-2 Vote Favors Benefit-Risk Profile of Imetelstat in Lower-Risk MDS
FDA ODAC Committee’s 12-2 Vote Favors Benefit-Risk Profile of Imetelstat in Lower-Risk MDS

March 15th 2024

Liso-Cel Receives FDA Approval for Relapsed or Refractory CLL/SLL
Liso-Cel Receives FDA Approval for Relapsed or Refractory CLL/SLL

March 15th 2024

Orca-T Provides Post-HCT Survival Benefits vs PTCy in Blood Cancers
Orca-T Provides Post-HCT Survival Benefits vs PTCy in Blood Cancers

March 4th 2024

Latest CME Events & Activities

What’s in Your Basket? Tumor Agnostic Trials and the Reshaping of Precision Medicine in Oncology: A Focus on TSC1/2 Mutations

View More

Expert Illustrations and Commentaries™: Evaluating the Potential for Novel Mechanistic Approaches to Overcome Clinical Gaps in the Care of Patients with LR-MDS

View More

Medical Crossfire®: Expert Perspectives in Geographic Atrophy – How Can We Prepare for a New Era of Treatment?

View More

Community Practice Connections™: Pre-Conference Workshop on Immune Cell-Based Therapy

View More

Clinical Vignettes™: Integrating Novel CAR T-Cell Therapies Across Lymphoid Malignancies with an Eye Toward the Future of Care

View More

The Latest on Acute Lymphocytic Leukemia

View More

Updates in Myelodysplastic Syndromes

View More

A Focus on Acute Myeloid Leukemia

View More

Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes

View More

Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma

View More

Go To PER in Chicago

May 31, 2024 - June 2, 2024

Register Now!

Patient, Provider, and Caregiver Connection™: Individualizing Care for Patients with Schizophrenia—Understanding Patient Challenges and the Role of Innovative Treatment

View More

Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!

View More

B-Cell Tumor Board: Rendering Real World Personalized Treatment Plans in CLL/SLL and MCL Through the Lens of Emerging BTKi Evidence

View More

Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer

View More

8th Annual School of Nursing Oncology™

August 10, 2024

Register Now!

7th Annual Live Medical Crossfire®: Hematologic Malignancies

View More

Community Practice Connections™: Integrating BTK Inhibitors Into the CLL/SLL and MCL Treatment Paradigm

View More

Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease

View More

42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®

November 13-15, 2024

Register Now!

Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?

View More

Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?

View More

Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!

View More

Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat

View More

Show Me the Data: How Do We Navigate the Latest Evidence on Novel Therapies, Combinations, and Clinical Trials Across MPN Care in the Context of Current Treatment Algorithms?

View More

Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?

View More

The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…

View More

Improving Outcomes in Autoimmune Hemolytic Anemias at the Intersection Between Hematology and Oncology Care

View More

Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board

View More

More News

© 2024 MJH Life Sciences

All rights reserved.